Novo Nordisk A/S (NVO)

DEADLINE ALERT for SOC, LMT, NVO, and LINE: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

LOS ANGELES, Aug. 20, 2025 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.

Novo Nordisk halts hiring as new CEO's restructuring continues

Novo Nordisk has initiated a hiring freeze as it looks to control costs under new boss Maziar Mike Doustdar. All markets and departments, apart from business-critical roles, will be affected by the pause, the company said.

Novo Nordisk to present Wegovy® and Ozempic® data showing life-saving cardiovascular benefits for people living with obesity and type 2 diabetes at the European Society of Cardiology Congress 2025

Bagsværd, Denmark, 20 August 2025 – Novo Nordisk today announced new data showing the cardiovascular protective benefits of Wegovy ® and Ozempic ® will be presented at the European Society of Cardiology (ESC) Congress 2025 from 29 August to 1 September in Madrid, Spain. New data will also include perspectives on the role of inflammation in a condition called atherosclerotic cardiovascular disease (ASCVD).

Deadline Alert: Novo Nordisk A/S (NVO) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit

LOS ANGELES, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming September 30, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Novo Nordisk A/S (“Novo Nordisk” or the “Company”) (NYSE: NVO) securities between May 7, 2025, to July 28, 2025, inclusive (the “Class Period”).

Novo Nordisk: Market Still Pricing It At Crisis Valuations

Novo Nordisk A/S is facing an unprecedented crisis of confidence as the tumble in its valuations reached extremely fearful levels. Novo remains the global leader in diabetes and obesity drugs, with strategic U.S. manufacturing expansion. Novo's free cash flow margins could recover through 2027 as it expands its manufacturing to take on Lilly and peers.

From Doubt To Action: Why I Bought Novo Nordisk After Earnings

Novo Nordisk A/S Q2 earnings were solid, but the guidance disappointed. My investment decision was based on a long-term outlook rather than this single quarter. Novo Nordisk's narrative shifted rapidly from crisis to opportunity due to underwhelming Eli Lilly trial results and Wegovy's new FDA approval for liver disease. NVO stock now trades at a deep discount, with valuation metrics at half their historical averages, despite maintaining strong revenue growth and innovation momentum.

GLP-1 drug Wegovy approved to treat liver disease, what's driving Q2 earnings results

Morning Brief anchor Julie Hyman breaks down the latest market news for August 18, 2025. Novo Nordisk's weight loss drug Wegovy is the first GLP-1 drug approved to treat liver disease.

INVESTOR REMINDER: Berger Montague Notifies Novo Nordisk A/S (NYSE: NVO) Investors of a Class Action Lawsuit and Deadline

PHILADELPHIA , Aug. 18, 2025 /PRNewswire/ -- Berger Montague PC is investigating claims under the federal securities laws against Novo Nordisk A/S (NYSE: NVO) ("Novo" or the "Company"), a global pharmaceutical company, headquartered in Denmark, after a class action lawsuit was filed against Novo. Investor Deadline: Investors who purchased or acquired Novo securities between May 7, 2025 through July 28, 2025 (the "Class Period"), may, no later than September 30, 2025 , seek to be appointed as a lead plaintiff representative of the class.

Novo Nordisk's Loss Is Eli Lilly's Gain, And Vice Versa

Novo Nordisk A/S's FDA approval for Wegovy in MASH and aggressive Ozempic pricing boost its position, despite recent stock declines and competitive pressure from Eli Lilly and Company. Both NVO and LLY face regulatory headwinds from U.S. drug pricing demands, but I believe much of the bad news is already priced in for both. Novo's strategic pricing, strong clinical data, and attractive valuation make it my preferred long-term pick, though both stocks offer upside from current levels.

Novo Nordisk to sell weight-loss drug for $499 to eligible customers

Cash-paying type 2 diabetes patients in the United States can now access Novo Nordisk's Ozempic for $499 per month through multiple pharmacy platforms.

Why is GDRX stock up 30% today? GoodRx strikes deal to sell Ozempic and Wegovy after Novo Nordisk's breakup with Hims

Share prices of GoodRx (NASDAQ: GDRX), the American healthcare company and telemedicine service, are currently soaring after the company announced that it will partner with Novo Nordisk to offer the lowest-ever out-of-pocket prices for Ozempic and Wegovy.

NVO Stock Up on FDA Nod for Wegovy in MASH: More Upside Ahead?

Novo Nordisk surges as Wegovy secures FDA approval for MASH, marking a breakthrough in liver care and expanding its blockbuster reach.

Top Stock Movers Now: Dayforce, Novo Nordisk, First Solar, and More

Major U.S. equities indexes were little changed Monday morning, ahead of retail sector earnings reports and comments from Federal Reserve Chair Jerome Powell due later in the week.

Novo Nordisk A/S (NVO) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

LOS ANGELES , Aug. 18, 2025 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to Novo Nordisk A/S ("Novo Nordisk" or the "Company") (NYSE: NVO) have opportunity to lead the securities fraud class action lawsuit.

Novo Nordisk's Wegovy receives FDA approval to treat serious liver disease

CNBC's Angelica Peebles joins 'Squawk on the Street' to discuss the latest news on Novo Nordisk, what new FDA approval on its Wegovy drug means for sales, and much more.

Novo Nordisk expands access to Ozempic, Wegovy through GoodRx and other platforms

Novo Nordisk (NYSE:NVO) shares moved higher on Monday after it was announced that US patients can access its diabetes drug Ozempic at a cheaper price through several platforms, expanding access to the therapy for those who do not have insurance coverage. Patients can pay $499 in cash per month through the drug's website, Novo Nordisk's patient assistance program, the company's direct-to-consumer online pharmacy and via drug savings platform GoodRx.

GoodRx Stock Spikes 35% on Novo Nordisk Collaboration. They're Offering Ozempic for $499 a Month.

GoodRx announces a collaboration with Novo Nordisk to make Ozempic cheaper for self-paying patients.

FDA Win Boosts Struggling Pharmaceutical Stock

Pharmaceutical powerhouse Novo Nordisk (NYSE:NVO) is charging 3.1% higher to trade at $54.10, after its weight-loss drug Wegovy landed Food and Drug Administration (FDA) approval to be used in the treatment of liver disease in the U.S. Today's pop comes just weeks after the company slashed its 2025 profit outlook and appointed a new CEO, resulting in a 21.8% bear gap on July 29, its worst drop on record.

Novo Nordisk's Weight-Loss Drug Wegovy Approved to Treat Liver Disease

U.S.-listed shares of Novo Nordisk (NVO) gained 4% in premarket trading after the Food and Drug Administration (FDA) approved the pharmaceutical firm's popular weight-loss drug, Wegovy, to treat a serious liver disease.

Novo Nordisk to offer Ozempic for $499 per month

Novo Nordisk said on Monday that it was launching a new offer for self-paying type 2 diabetes patients to access authentic Ozempic for $499 per month.

Novo Nordisk offers diabetes drug Ozempic for less than half the price for cash-paying U.S. patients

Novo Nordisk said it now offers cash-paying U.S. patients its blockbuster diabetes treatment Ozempic for less than half its monthly list price through multiple platforms. Patients can pay $499 in cash per month for three dose sizes of Ozempic through the drug's official website, Novo Nordisk's patient assistance program, the company's recently launched direct-to-consumer online pharmacy and drug savings company GoodRx, among other platforms.

Class Action Filed Against Novo Nordisk A/S (NVO) - September 30, 2025 Deadline to Join - Contact The Gross Law Firm

NEW YORK , Aug. 18, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Novo Nordisk A/S (NYSE: NVO). Shareholders who purchased shares of NVO during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

SHAREHOLDER ALERT: Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Novo Nordisk A/S (NYSE: NVO)

NEW YORK, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the securities of Novo Nordisk A/S (“Novo” or the “Company”) (NYSE: NVO) between May 7 , 202 5 and July 28 , 202 5, inclusive. Should You Join This Class Action Lawsuit?

Novo Nordisk Stock Is Jumping. Weight-Loss Drug Wegovy Has Something to Do With It.

Novo Nordisk makes the wildly popular GLP-1 drug semaglutide which it sells under the brand name Wegovy for weight-loss and Ozempic for diabetes.

Novo Nordisk Shares Rise After FDA Approves Wegovy for Liver Disease

Novo Nordisk shares pop 5% after Wegovy receives U.S. approval for liver disease

The firm was granted U.S. approval for the treatment of metabolic dysfunction-associated steatohepatitis in adults with moderate to advanced liver fibrosis.

NVO Investors Have Opportunity to Lead Novo Nordisk A/S Securities Fraud Lawsuit with the Schall Law Firm

LOS ANGELES , Aug. 18, 2025 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Novo Nordisk A/S ("Novo Nordisk" or "the Company") (NYSE: NVO) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 7, 2025 and July 28, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before September 30, 2025.

Novo Nordisk shares are rising. The FDA approves another use for Wegovy.

Novo Nordisk shares were climbing Monday after the Food and Drug Administration approved the popular weight-loss drug Wegovy to treat a form of liver disease.

Shares in Novo Nordisk rise after Wegovy gets US nod for liver disease treatment

Shares in Novo Nordisk rose on Monday, after it got U.S. approval for its weight-loss drug Wegovy to treat a serious liver condition, positive news for the drugmaker that lost more than one-third of its market value in recent weeks.

Novo Nordisk's Wegovy gets accelerated US FDA approval for liver disease MASH

Novo Nordisk said on Friday the U.S. Food and Drug Administration had granted accelerated approval for its weight-loss drug Wegovy to treat a serious liver condition known as metabolic dysfunction-associated steatohepatitis.